Emerging as a noteworthy breakthrough in the fight against obesity, Retatrutide is capturing considerable attention . This treatment combines effects of two known GLP-1 binding agonists, liraglutide, plus an unique glucose-dependent incretin component. Initial study findings have demonstrated imp